Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease

References

• Pearson C, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995; 123: 132–42
   PubMed Web of Science ®Google Scholar
• George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91: 1711–4
   PubMed Web of Science ®Google Scholar
• Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329–39
   PubMed Web of Science ®Google Scholar
• Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401–6
   PubMed Web of Science ®Google Scholar
• Korelitz BI, Zlantanic J, Goel F, Fuller S. Allergic reactions to 6-mercaptopurine in the management of inflammatory bowel disease. J Clin Gastroenterol 1999; 28: 341–4
   PubMed Web of Science ®Google Scholar
• Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann Intern Med 1989; 111: 641–9
   PubMed Web of Science ®Google Scholar
• Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081–5
   PubMed Web of Science ®Google Scholar
• Sandborn, W, Sutherland, L, Pearson, D, May, G, Modigliani, R, Prantera, C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2001;3.
   Google Scholar
• Steinhart, AH, Hawkey, CJ, Modigliani, R. 6-Mercaptopurine and azathioprine for maintaining remission in ulcerative colitis. Cochrane Database Syst Rev 2001; 3.
   Google Scholar
• Bouhnik Y, Lemann M, Nary JY, Scemama G, Tai R, Matuchansky C, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215–9
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699–706
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001; 7: 190–1
   PubMed Web of Science ®Google Scholar
• Derijks JJL, de Jong JD, Gilissen PLL, Engels GJBL, Hooymans MP, Jansen BMJJ, et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003; 15: 63–7
   PubMed Web of Science ®Google Scholar
• Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, et al. Remission maintenance by thioguanine in chronic active Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1459–64
   PubMed Web of Science ®Google Scholar
• Bonaz B, Boitard J, Marteau P, Lemann M, Coffin B, Flourie B, et al. Thioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003; 15: 401–8
   Web of Science ®Google Scholar
• Herrlinger KR, Kreisel W, Schwab M, Schoelmerich J, Fleig WE, Ruhl A, et al. 6-thioguanine: efficacy and safety in chronic active Crohn's disease. Aliment Pharmacol Ther 2003; 17: 503–8
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliaukas EA. Thioguanine (6-TG): a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003; 98: 1058–63
   PubMed Web of Science ®Google Scholar
• Shastri S, Dubinsky MC, Fred Poordad S, Vasiliauskas EA, Geller SA. Early nodular hyperplasia occurring with inflammatory bowel disease in association with thioguanine therapy. Arch Pathol Lab Med 2004; 128: 49–53
   PubMed Web of Science ®Google Scholar
• Kane S, Cohen SM, Hart J. Acute sinusoidal obstruction syndrome after 6-thioguanine therapy in Crohn's disease. Inflamm Bowel Dis 2004; 10: 652–4
   PubMed Web of Science ®Google Scholar
• Ibarrola C, Castellano VM, Colina F. Focal hyperplastic hepatocellular nodules in hepatic venous outflow obstruction: a clinicopathological study of four patients and 24 nodules. Histopathology 2004; 44: 172–9
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease. Gastroenterology 2003; 125: 298–303
   PubMed Web of Science ®Google Scholar
• Geller SA, Dubinsky MC, Poordad FF, Vasiliauskas EA, Cohen AH, Abreu MT, et al. Early nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in IBD. Am J Surg Pathol 2004; 28: 1204–11
   PubMed Web of Science ®Google Scholar
• Seiderer J, Zech CJ, Reinisch W, Lukas M, Diebold J, Wrba F, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 2005; 43: 303–9
   PubMed Web of Science ®Google Scholar
• Myren, J, Bouchier, IAD, Watkinson, Softley, A, Clamp, SE, Dombal, FT. The O.M.G.E. multinational inflammatory bowel disease survey 1976–1982. A further report on 2657 cases. Scand J Gastroenterol 1984; Suppl 95:1–27.
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841–5
   PubMed Web of Science ®Google Scholar
• Stoneham S, Lennard L, Coen P, Lilleyman J, Saha V. Veno-occlusive disease in patients receiving thioguanines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematology 2003; 123: 100–2
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904–15
   PubMed Web of Science ®Google Scholar